Abstract
Repeated platelet transfusion often induces alloimmunization to HLA-antigens resulting in a state of refractoriness of the thrombocytopenic patient. Such patients can be successfully treated with platelet concentrates from an HLA compatible sibling donor [1]. Also matched platelets from unrelated donors can survive normally in the highly sensitized patient [2–4]. The HLA-antigens are coded by a very polymorphic genetic system. Therefore even in a large pool of blood bank donors chances of finding a perfectly matched donor are low. However in the alloimmunized thrombocytopenic recipient the effectiveness of transfusion of platelets from donors selectively mismatched for crossreactive antigens does not differ from the cell increment obtained with HLA fully matched platelets [5,6]. A positive crossmatch as a result of circulating antibodies against donor incompatibilities is associated with a poor transfusion response. HLA-antibody screening enables us to determine which donor HLA-incompatibilities will not lead to a positive crossmatch and therefore can be considered as acceptable mismatches. The aim of this paper is to summarize the methods which are currently used in routine HLA-typing and antibody screening.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Yankee RA, Grunet FC, Rogentine GN. Platelet transfusion therapy, the selection of compatible platelet donors for refractory patients by lymphocyte HLA typing. N Engl J Med 1969;281:1208–12.
Thorsby E, Helegesen A, Gjemdal T. Repeated platelet transfusion from HLA compatible unrelated and sibling donors. Tissue Antigens 1972;2:397–404.
Yankee RA, Graff KS, Dowling R, Dowling R, Henderson ES. Selection of unrelated compatible platelet donors by lymphocyte HLA-matching. N Engl J Med 1973;15:760–4.
Lohrmann HP, Bull MI, Decter JA, Yankee RA, Graw RR Jr. Platelet transfusion from HLA compatible donors to alloimmunized patients. Ann Intern Med 1974;80:9–14.
Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH. Successful transfusion of platelets ‘mismatched’ for HLA-antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977;2:19–26.
Dahlke MB, Weiss KL. Platelet transfusion from donors mismatched for cross-reactive HLA-antigens. Transfusion 1984;24:299–302.
Moore SB. The human MHC and its relevance to transfusion practice. In: Smit Sibinga CTh, Das PC, Engelfriet CP (eds). White cells and platelets in blood transfusion. Boston, Dordrecht, Lancaster: Martinus Nijhoff 1987:1–12.
Welsh KI, Burgos H, Batchelor JR. The immune response to allogeneic rat platelets: Ag-B antigens in matrix for lacking Ia. Eur J Immunol 1977;7:267–72.
Batchelor JR, Welsh KI, Burgos H. Transplantation antigens per se are poor immunogens within a species. Nature 1978;273:54–6.
Claas FH, Smeenk RJT, Schmidt R, van Steenbrugge GJ, Eernisse JG. Alloimmunization against the MHC antigens after platelet transfusion is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9:84–9.
Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA-antibodies by the administration of leukocyte-poor blood components. Exp Hematol 1981;9:77–83.
Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Rully JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;52:815–20.
Fischer M, Chapman JR, Ting A, Morris PJ. Alloimmunization to HLA-antigens following transfusion with leukocyte-poor and purified platelet suspensions. Vox Sang 1985;49:331–5.
Murphy MF, Metcalfe P, Thomas H, et al. Use of leukocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Brit J Haematol 1986;62:529–34.
Pegels JG, Bruynes EC, Engelfriet CP, von dem Borne AEG Kr. Serological studies in patients on platelet and granulocyte-substitution therapy. Brit J Haematol 1982;52:59–68.
Bruning JW. Automatic reading of HLA-ABC typing and screening, the propi-dium iodide (PI) method. Hum Immunol 1982;5:225–31.
Bruning JW, Kardol MJ, Arentzen R. Carboxyfluorescein fluorochromasia assays. I. Non-radioactively labeled cell mediated lympholysis. J Immunol Methods 1980;33:33–44.
Van Rood JJ, van Leeuwen A. Simultaneous detection of two cell populations by two-color fluorescence and application to the recognition of B-cell determinants. Nature 1976;262:795–7.
Brand A, van Leeuwen A, Eernisse JG, van Rood JJ. Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence test. Blood 1978;51:781–8.
Waters AH, Minchinton RH, Bell R, Foros JM, Lister TA. A crossmatching procedure for the selection of platelet donors for alloimmunized patients. Brit J Haematol 1981;48:59–68.
Von dem Borne AEG Kr. Platelet antibody detection. In: Smit Sibinga CTh, Das PC, Engelfriet CP (eds). White cells and platelets in blood transfusion. Boston, Dordrecht, Lancaster: Martinus Nijhoff 1987:261–7.
Nordhagen R, Flaatzen ST Chloroquine removal of HLA-antigens from platelets for the platelet immunofluorescence test. Vox Sang 1985;48:156–9.
Metcalfe P, Minchinton RM, Murphy MF, Waters AH. Use of chloroquine-treated granulocytes and platelets in the diagnosis of immune cytopenias. Vox Sang 1985;49:340–5.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Beelen, J.M. (1987). HLA-Matching and Crossmatching in Platelet Transfusion. In: Sibinga, C.T.S., Das, P.C., Engelfriet, C.P. (eds) White cells and platelets in blood transfusion. Developments in Hematology and Immunology, vol 19. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2089-0_22
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2089-0_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9238-8
Online ISBN: 978-1-4613-2089-0
eBook Packages: Springer Book Archive